Richa Shah

Publication Activity (10 Years)

Years Active: 2023-2023
Publications (10 Years): 7

Top Topics

Cross Sectional

Acute Lymphoblastic Leukemia

Top Venues

Journal of comparative effectiveness research

This page only lists publications with an associated author ORCID identifier.

Publications

T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research (2023)
T Alexander Russell-Smith, Louise B Murphy, Amy Nguyen, Cori Blauer-Peterson, Marilou Terpenning, Feng Cao, Shiqiang Li, Tim Bancroft, Noah S Webb, Stephanie Dorman, Richa Shah
Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting. Journal of comparative effectiveness research 13 (2) (2023)